TGFBR2 and esophageal cancer: Current clinical trials, evaluate anti-MUC1 CAR T cells with PD-1 knockout in advanced esophageal cancer (NCT03706326) and anti-EGFR CAR T cells with TGFBR2 knockout in EGFR-positive solid tumors (NCT04976218).